KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Non Operating Income (2016 - 2026)

Palvella Therapeutics has reported Non Operating Income over the past 9 years, most recently at $723000.0 for Q3 2022.

  • Quarterly Non Operating Income rose 6.64% to $723000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2022, up 939.38% year-over-year, with the annual reading at $727000.0 for FY2025, 654.96% up from the prior year.
  • Non Operating Income was $723000.0 for Q3 2022 at Palvella Therapeutics, up from $676000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $1.2 million in Q2 2018 and troughed at -$1.8 million in Q4 2020.
  • The 5-year median for Non Operating Income is $229000.0 (2022), against an average of $113421.1.
  • Year-over-year, Non Operating Income plummeted 7625.0% in 2018 and then skyrocketed 1573.33% in 2021.
  • A 5-year view of Non Operating Income shows it stood at $331000.0 in 2018, then crashed by 46.53% to $177000.0 in 2019, then crashed by 1135.59% to -$1.8 million in 2020, then skyrocketed by 120.62% to $378000.0 in 2021, then skyrocketed by 91.27% to $723000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Non Operating Income are $723000.0 (Q3 2022), $676000.0 (Q2 2022), and $229000.0 (Q1 2022).